Alfuzosin delays cardiac repolarization by a novel mechanism.


The United States Food and Drug Administration (FDA) uses alfuzosin as an example of a drug having QT risk in humans that was not detected in nonclinical studies. FDA approval required a thorough clinical QT study (TCQS) that was weakly positive at high doses. The FDA has used the clinical/nonclinical discordance as a basis for mandatory TCQS, and this… (More)


8 Figures and Tables

Cite this paper

@article{Lacerda2008AlfuzosinDC, title={Alfuzosin delays cardiac repolarization by a novel mechanism.}, author={Ant{\'o}nio Lacerda and Yuri A. Kuryshev and Yuan Chen and Muthukrishnan Renganathan and Heather Eng and Sanjay J Danthi and James W Kramer and Tianen Yang and Arthur M. Brown}, journal={The Journal of pharmacology and experimental therapeutics}, year={2008}, volume={324 2}, pages={427-33} }